Skip to main content
Fig. 2 | Virology Journal

Fig. 2

From: A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy

Fig. 2

Schematic of the construction and characterization of oHSV2-IL12, -PD1v, -IL15, -IL7 × CCL19, GM-CSF. A The oHSV2 vectors were constructed based on the HG52 strain. Modifications include ICP47 and ICP34.5 genes deletion and the insertion of the related transgenes. IL7 × CCL19 means that IL7 and CCL19 were linked through the 2A peptide. B PCR identification of the inserted sequences. Lane M: marker, lane 1: negative control, lane 2–6 are oHSV2-IL7 × CCL19, GM-CSF, IL12, PD1v and IL15, respectively. C Western blot identification of PD1v (approximately 33 kDa) expression in oHSV2-PD1v infected Vero cells. Lane 1, mock-treated control, lane 2, oHSV2-GFP treated control, lane 3, oHSV2-PD1v infected Vero cells

Back to article page

Virology Journal

ISSN: 1743-422X